Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

NCT03797625 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Irinotecan
DRUG: DDP
DRUG: Endostar

Sponsor

Fudan University